1089212-38-3

Basic information

• Product Name: 4-broMo-3-(difluoroMethyl)-1-Methyl-1H-pyrazole
• Synonyms: 4-broMo-3-(difluoroMethyl)-1-Methyl-1H-pyrazole;4-Bromo-3-difluoromethyl-1-methylpyrazole
• CAS NO: 1089212-38-3
• Molecular Formula: C₅H₅BrF₂N₂
• Molecular Weight: 211.0074064
• Mol File: 1089212-38-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 235℃
• Flash Point: 96℃
• Appearance: /
• Density: 1.79
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-broMo-3-(difluoroMethyl)-1-Methyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-3-(difluoroMethyl)-1-Methyl-1H-pyrazole(1089212-38-3)
• EPA Substance Registry System: 4-broMo-3-(difluoroMethyl)-1-Methyl-1H-pyrazole(1089212-38-3)

Safety Data

• Hazardous Substances Data: 1089212-38-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-3-(difluoromethyl)-1-methyl-1H-pyrazole is a chemical compound with the molecular formula C5H5BrF2N2. It is a pyrazole derivative with a bromo substituent at the 4-position and a difluoromethyl group at the 3-position. 4-Bromo-3-(difluoromethyl)-1-methyl-1H-pyrazole is also known as 'fipronil' and is commonly used as an insecticide to control a wide range of pests, including termites, ants, and beetles. Fipronil acts by blocking the GABA-gated chloride channels in the central nervous system of insects, leading to hyperexcitation and ultimately death. It is classified as a phenylpyrazole insecticide and is used in both agricultural and residential settings. Fipronil has been the subject of controversy due to its potential impact on non-target organisms and the environment, but it remains a commonly used insecticide in many parts of the world.

Upstream product

• 146941-72-2 4-bromo-1-methyl-1H-pyrazol-3-ylamine 
• 1089212-45-2 4-bromo-3-dichloromethyl-1-methylpyrazole 
• 1089212-37-2 3-(difluoromethyl)-1-methyl-1H-pyrazole 
• 5775-82-6 4-bromo-1,3-dimethyl-1H-pyrazole 
• 694-48-4 1,3-dimethyl-1H-pyrazole 

Downstream Products

• 141573-95-7 ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate 
• 176969-34-9 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid 
• 881685-58-1 isopyrazam 
• 581809-46-3 bixafen 
• 874967-67-6 sedaxane 

Relevant articles and documents

Preparation method of 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester

The invention discloses a preparation method of 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: with 1,3-dimethylpyrazole as a raw material, carrying out halogenation to obtain 4-halogenated-1,3,5-tetrahydronaphthalene; carrying out a reaction under the conditions of a bromination reagent and AIBN and hydrolysis with hexamethylenetetramine to obtain 4-halogen-1-methyl-1H-pyrazole-3-formaldehyde, then performing a reaction with a fluorination reagent to obtain 4-halogen-3-difluoromethyl-1-methylpyrazole; finally carrying out a reaction on the 4-halogen-3-difluoromethyl-1-methylpyrazole and a Grignard reagent to obtain 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester. The method is simple and convenient to operate and high in reaction yield, the purity of the obtained product can reach 99.5% or above, and the method has a potential process amplification prospect.

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.